Gut health, diet, and quality of life in CVID
Part of Immune system & allergy clinical trials.
This study looks at the gut microbiome (the bacteria in your digestive system), diet, and quality of life in people with CVID, a condition that affects the immune system. It compares those who receive immunoglobulin therapy (antibody treatment) with those who do not, to see if there are differences that might help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CVID (common variable immunodeficiency).
- You are 18 years old or older.
- You have not started taking antibiotics at full treatment doses within the last 30 days.
- You have not started taking immunomodulators (medicines that change how your immune system works) within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study examines how the immune system malfunctions in patients with common variable immunodeficiency (CVID)—a condition where the body doesn't make enough antibodies to fight infections. Researchers want to understand the genetics and immune patterns to help develop better treatments. Family members may also be asked to participate to help identify genetic causes.
This study looks at how often “SPAD” happens in adults who get repeated bacterial infections in the chest or sinuses. It aims to better understand your infection frequency and related immune test results, which may help guide future care.
This study looks at a specific type of immune cell in people with Common Variable Immune Deficiency (CVID). It aims to learn more about how these cells behave and may help guide better treatments for this condition.
This trial looks at how breathing tests (spirometry) can help guide treatment decisions for people with CVID and airway disease who are already on immune globulin (IG) therapy. It may help your care team better monitor lung function using a specific breathing-test pattern.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
Hear when a new CVID trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.